Table 1. Study characteristics and summary findings.
| Study | N | Design | Demographics Median age (years) | Gender (M/F) | Patient population | Treatment arms | 3year OS(%) | 3year LRC(%) | 5year OS(%) | 5year LRC(%) |
|---|---|---|---|---|---|---|---|---|---|---|
| Kua VF et al. 2013 | 41 | retrospective study | All above 30 | CDDP:15/2 CBDCA:15/9 | metastatic and recurrent SCCHN and NPC Race: Malays, Chinese and India |
CDDP: CDDP 75mg/m2,D1+5FU 750 mg/m2, D1-5 (n = 17) CBDCA: CBP AUC 5, D1+5FU 500 mg/m2 D1-2+5FU 500mg/m2, D1-2, bolus (n = 24) |
- - |
- - |
- - |
- - |
| A.C.Wilkins et al.2013 | 130 | matched-pair analysis | CDDP:58 CBDCA:59 |
CDDP:51/11 CBDCA:49/16 |
locally advanced SCCHN(except NPC) Stage III-IV. United Kindom |
CDDP: RT+DDP (100mg/m2, D1,29 (n = 65) CBDCA: RT+CBP (AUC5 D1,29 (n = 65) |
Cis:68 Cb:59 |
Cis:79 Cb:87 |
Cis:61.5 Cb:55.4 |
- - |
| M.Kreppel et al.2012 | 53 | retrospective study | - | - | locally advanced squamous cell carcinoma of maxillary sinus, stage II-IV. Germany |
CDDP: Neoadjuvant RCT (RT+DDP 40mg/m2/day,D1-5)+surgery (n = 33) CBDCA: Neoadjuvant RCT (RT+CBP 70mg/m2/day)+ surgery (n = 20) |
- - |
- - |
Cis:37.2 Cb:31.7 |
Cis:63.9 Cb:49.4 |
| D.Rades et al.2012 | 106 | retrospective study | - | CDDP:47/18 CBDCA:32/9 |
locally advanced squamous cell carcinoma of oropharynx and oral cavity (stage III/IV) Germany |
CDDP: Surgery+ CCRT: RT+DDP20 mg/m2,D1—5, D29—33 (n = 65) CBDCA: Surgery+ CCRT :RT+ CBP AUC 1.5,D1—5, D29—33 (n = 41) |
Cis:78 Cb:51 |
Cis:85 Cb:62 |
Cis:66.6 Cb:37.6 |
- - |
| I.Chitapanarux et al.2007 | 206 | Randomized,non-inferiority trial | CDDP:46 CBDCA:50 |
CDDP:57/44 CBDCA:69/36 |
locally advanced NPC (stage III-IV) Thailand |
CDDP:CCRT:RT+DDP(100mg/m2/day,D1,22,43)+Ad-CT:DDP(80mg/m2)+5-FU (1000mg/m2/day,96h), every 4 weeks×3 cycles (n = 110) CBDCA:CCRT:RT+CBP(100mg/m2/day,D1,8,15,22,29,36)+Ad-CT:CBP:AUC5+5-FU (1000mg/m2/day,96h), every 4 weeks×3 cycles (n = 110) |
Cis:78.6 Cb:79.8 |
- - |
- - |
- - |
| A.Homma et al.2004 | 119 | randomized, phase II study | CDDP:61.5 CBDCA:62 |
CDDP:54/5 CBDCA:59/1 |
Locally SCCHN, excluding cancers of glottic region, NPC, and paranasal sinus lesions, stageII-IV Japan |
CDDP:CCRT: DDP4mg/m2/day,D1-28+RT (n = 59) CBDCA: CCRT: CBP100mg/m2,D1.8.15.22 +RT (n = 60) |
Cis:68.5 Cb:80.2 |
Cis:38.2 Cb:57.4 |
Cis:66 Cb:71.4 |
Cis:35.5 Cb:56.2 |
| Deng LC et al.1999 | 57 | retrospective study | CDDP:51 CBDCA:53 |
CDDP:20/11 CBDCA:18/8 |
locally advanced SCCHN, stage III-IV. P.R.China | CDDP: Neoadjuvant CT (DDP100 mg/m2,D1+5FUD1-5,1000mg/m2)+RT (n = 31) CBDCA: Neoadjuvant CT (CBP300 mg/m2,D1+5FU,D1-5,1000mg/m2)+RT (n = 26) |
- | - | - | - |
| Deng KK2009 | 74 | Prospective non-randomized control study | CDDP:55 CBDCA:54 |
CDDP:25/13 CBDCA:24/12 |
Stage II-IV NPC P.R.China |
CDDP: induction CT (DDP 20mg/m2+5-FU 750mg/m2,D1-5)+CCRT(DDP20mg/m2+5-FU750mg/m2,D21-26,43-48+RT) (n = 38) CBDCA: induction CT (CBP50mg/m2+5-FU750mg/m2,D1-5)+CCRT(CBP50mg/m2+5-FU750mg/m2,D21-26,43-48+RT) (n = 36) |
- - |
- - |
- - |
- - |
| Wen QL et al.2013 | 176 | retrospective study | - - |
CDDP:49/39 CBDCA:52/36 |
Locally advanced NPC, stage III-IV P.R.China |
CDDP: CCRT: RT+DDP40mg/m2, weekly (n = 88) CBDCA: CCRT: RT+CBP60mg/m2, weekly (n = 88) |
- - |
- - |
- - |
- - |
| Ge W et al.1998 | 34 | retrospective study | - - |
CDDP:13/4 CBDCA:13/4 |
Middle and advanced NPC, N2-N3 P.R.China |
CDDP: neoadjuvant CT (DDP 100mg/m2D1+5-FU1000mg/m2D1-5)+RT (n = 17) CBDCA: neoadjuvant CT (CBP 300mg/m2D1+5-FU 1000 mg/m2D1-5)+RT(n = 17) |
- - |
- - |
- - |
- - |
| De Andres et al.1995 | 95 | Prospective,randomized,nonblind trial | CDDP:55 CBDCA:50 |
CDDP:46/3 CBDCA:43/3 |
Locally advanced SCCHN, stage IV-M0 except NPC Spain |
CDDP: neoadjuvant CT (DDP 100mg/m2+5-FU5000mg/m2,120h,,D1,22,43)×3 courses+RT (n = 49) CBDCA: neoadjuvant CT (CBP 400mg/m2,24h+5-FU5000mg/m2,120h,D1.22.43)×3 courses+RT (n = 46) |
- - |
- - |
Cis:49 Cb:25 |
- - |
| N Fuwa et al.2008 | 60 | retrospective study | CDDP:77 CBDCA:73 |
- | Locally advanced oral cavity cancer, stage III-IV, except carcinoma of the base of tongue Japan |
CDDP: CCRT:RT+DDP (continuous arterial injection,20-30mg/m2,repeated 6-7 times) (n = 21) CBDCA: CCRT:RT+CBP(arterial injection, AUC 6-8,repeated 6-7 times) (n = 39) |
Cis:55.07 Cb:30.77 |
Cis:61.39 Cb:60.58 |
- | - |
DDP/ Cis= cisplatin; CBP/ Cb= carboplatin.